Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir.

The Journal of infectious diseases - 1 Dec 2011

Canducci Filippo, Ceresola Elisa R, Boeri Enzo, Spagnuolo Vincenzo, Cossarini Francesca, Castagna Antonella, Lazzarin Adriano, Clementi Massimo

Abstract excerpt

Novel integrase inhibitors are in advanced clinical development, and cross-resistance data are needed to consider the possibility to plan a sequential usage within this class of antiretroviral drugs. Ex vivo phenotypic assays were conducted on 11 wild-type and 27 fully replicating recombinant viruses obtained from 11 patients failing previous raltegravir-containing regimens. Dolutegravir maintained its activity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Heterocyclic Compounds, 3-Ring
Share to HIV Integrase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Integrase Inhibitors

Share to Inhibitory Concentration 50

Share to Oxazines

Share to Pyridones

Share to Pyrrolidinones

Share to Raltegravir Potassium

Source

Identifiers

PMID: 21984737
DOI: 10.1093/infdis/jir636

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir.PMID 21984737Read ↗

Cross-Resistance Profile Determination of Two Second-Generation HIV-1 Integrase Inhibitors Using a Panel of Recombinant Viruses Derived from Raltegravir-Treated Clinical IsolatesSemantic proximity Read ↗

Will drug resistance against dolutegravir in initial therapy ever occur?Semantic proximity Read ↗

Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance.Semantic proximity Read ↗

New dolutegravir resistance pattern identified in a patient failing antiretroviral therapySemantic proximity Read ↗

In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravirSemantic proximity Read ↗

Evolution of HIV integrase resistance mutations.Semantic proximity Read ↗

Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.Semantic proximity Read ↗

Emerging patterns and implications of HIV-1 integrase inhibitor resistanceSemantic proximity Read ↗

Accumulation of Multiple Mutations In Vivo Confers Cross-Resistance to New and Existing Integrase InhibitorsSemantic proximity Read ↗

High frequency of dolutegravir resistance in patients failing a raltegravir-containing salvage regimen.Semantic proximity Read ↗

Development of the R263K Mutation to Dolutegravir in an HIV-1 Subtype D Virus Harboring 3 Class-Drug ResistanceSemantic proximity Read ↗

A Comprehensive Literature Review of Treatment-Emergent Integrase Resistance with Dolutegravir-Based Regimens in Real-World Settings.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.